Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 252004
                    [Title] => Treatment for Barrett’s crucial in preventing esophageal adenocarcinoma
                    [Summary] => 
(Conclusion)
After a mean follow-up of 45 months, 42 patients (40 percent) had no histological evidence of BE, 43 patients (41 percent) had no dysplasia, 14 patients (13 percent) had low-grade dysplasia, two patients (2 percent) had high-grade dysplasia and four patients (4 percent) developed cancer. Based on current estimates of cancer incidence in high-grade and low-grade dysplasia, 20 cancers would have been anticipated in this group versus the four that did occur (P<0.001).


                    [DatePublished] => 2004-05-31 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 251900
                    [Title] => Treatment for Barrett’s crucial in preventing esophageal adenocarcinoma
                    [Summary] => Adenocarcinoma of the esophagus is increasing at an alarming rate. In the United States there are approximately 6,250 new cases diagnosed every year. Barrett’s esophagus (BE), which affects approximately 700,000 people in the United States, increases the risk of developing adenocarcinoma of the esophagus 30- to 125-fold. Because the development of cancer in BE takes place over time, physicians can provide patients with interventions, according to a professor of clinical medicine at Columbia University College of Physicians and Surgeons, New York City.


                    [DatePublished] => 2004-05-30 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

DYSPLASIA

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 252004
                    [Title] => Treatment for Barrett’s crucial in preventing esophageal adenocarcinoma
                    [Summary] => 
(Conclusion)
After a mean follow-up of 45 months, 42 patients (40 percent) had no histological evidence of BE, 43 patients (41 percent) had no dysplasia, 14 patients (13 percent) had low-grade dysplasia, two patients (2 percent) had high-grade dysplasia and four patients (4 percent) developed cancer. Based on current estimates of cancer incidence in high-grade and low-grade dysplasia, 20 cancers would have been anticipated in this group versus the four that did occur (P<0.001).


                    [DatePublished] => 2004-05-31 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 251900
                    [Title] => Treatment for Barrett’s crucial in preventing esophageal adenocarcinoma
                    [Summary] => Adenocarcinoma of the esophagus is increasing at an alarming rate. In the United States there are approximately 6,250 new cases diagnosed every year. Barrett’s esophagus (BE), which affects approximately 700,000 people in the United States, increases the risk of developing adenocarcinoma of the esophagus 30- to 125-fold. Because the development of cancer in BE takes place over time, physicians can provide patients with interventions, according to a professor of clinical medicine at Columbia University College of Physicians and Surgeons, New York City.


                    [DatePublished] => 2004-05-30 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

Treatment for Barrett’s crucial in preventing esophageal adenocarcinoma

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | May 31, 2004 - 12:00am

(Conclusion) After a mean follow-up of 45 months, 42 patients (40 percent) had no histological evidence of BE, 43 patients (41 percent) had no dysplasia, 14 patients (13 percent) had low-grade dysplasia, two patients...

Opinion

Treatment for Barrett’s crucial in preventing esophageal adenocarcinoma

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | May 30, 2004 - 12:00am

Adenocarcinoma of the esophagus is increasing at an alarming rate. In the United States there are approximately 6,250 new cases diagnosed every year. Barrett’s esophagus (BE), which affects approximately 700,000...

Opinion